Top

Published in:

01-01-2013 | Review Article

The changing role of axillary lymph node dissection for breast cancer

Authors: Masakuni Noguchi, Emi Morioka, Yukako Ohno, Miki Noguchi, Yasuharu Nakano, Takeo Kosaka

Published in: Breast Cancer | Issue 1/2013

Abstract

Currently, it is standard practice that patients with negative sentinel lymph nodes (SLNs) do not undergo axillary lymph node dissection (ALND), whereas ALND is mandated in those with positive SLNs. However, the Z0011 trial showed that ALND could be safely omitted in selected patients with positive SLNs. This article presents a review and discussion of the current role and practice of ALND in the surgical management of breast cancer. A review of the English-language medical literature was performed using the MEDLINE database and cross-referencing major articles on the subject. It may be concluded that ALND can be avoided not only in patients with negative SLNs but also in those with positive SLNs who undergo breast-conserving therapy with whole-breast irradiation and appropriate systemic therapy. However, the omission of ALND would be indicated only in patients with a low axillary tumor burden. On the other hand, ALND remains a standard method of treating regional disease not only in patients with clinically positive nodes but also in other SLN-positive patients who do not meet the above criteria. Although the role of ALND has been limited to the prevention of axillary recurrence, SLN biopsy with whole-breast irradiation and systemic therapy can replace ALND in patients with a low axillary tumor burden.

Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674–81.PubMedCrossRef

Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.PubMedCrossRef

Noguchi M, Miwa K, Michigishi T, Yokoyama K, Nishijima H, Takanaka T, et al. The role of axillary lymph node dissection in breast cancer management. Breast Cancer. 1997;4:143–53.PubMedCrossRef

Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–401.PubMedCrossRef

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.PubMedCrossRef

Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600.PubMedCrossRef

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRef

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2011;252:426–32.

Morrow M, Giuliano AE. To cut is to cure: can we really apply Z11 in practice? Ann Surg Oncol. 2011;18:2413–5.PubMedCrossRef

10.

Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus conference. Breast Care. 2011;2011(6):136–41.CrossRef

11.

Halsted W. The results of operations for cure of cancer of the breast performed at Johns Hopkins Hospital. Johns Hopkins Hosp Bull. 1895;4:497.

12.

Halsted W. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1019.

13.

Noguchi M. Does regional treatment improve the survival in patients with operable breast cancer? Breast Cancer Res Treat. 2002;76:269–82.PubMedCrossRef

14.

Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian meta-analysis. Ann Surg Oncol. 1999;6:109–66.PubMedCrossRef

15.

Hayward JL. The Guy’s Hospital trials on breast conservation. In: Harris JR, Hellman S, Silen W, editors. Conservative management of breast cancer. Philadelphia: J.B. Lippincott; 1983. p. 77–90.

16.

Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg. 1987;122:1244–7.PubMedCrossRef

17.

Hayward JL. The Guy’s trial of treatment of “early” breast cancer. World J Surg. 1977;1:314–6.PubMedCrossRef

18.

Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. Invasion, size, and nodal status involvement dramatically decreasing as result of mammographic screening. Arch Surg. 1996;131:301–8.PubMedCrossRef

19.

Morrow M. Axillary dissection: when and how radical? Semin Surg Oncol. 1996;12:321–7.PubMedCrossRef

20.

Noguchi M, Katev N, Miyazaki I. Diagnosis of axillary lymph node metastases in patients with breast cancer. Breast Cancer Res Treat. 1996;40:283–93.PubMedCrossRef

21.

Rubio IT. Positive sentinel lymph node: new controversies regarding axillary node dissection. J Surg Oncol. 2006;93:517–8.PubMedCrossRef

22.

Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer. J Clin Oncol. 1999;17:1720–6.PubMed

23.

Noguchi M. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer. Eur J Surg Oncol. 2008;34:129–34.PubMedCrossRef

24.

Singletary SE, Greene FL. Revision of breast cancer staging: the 6th edition of the TNM classification. Semi Surg Oncol. 2003;21:53–9.CrossRef

25.

Noguchi M. Therapeutic relevance of breast cancer micrometastases in sentinel lymph nodes. Br J Surg. 2002;89:1505–15.PubMedCrossRef

26.

Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91:1245–52.PubMedCrossRef

27.

Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection of node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.PubMedCrossRef

28.

Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27:4679–84.PubMedCrossRef

29.

Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10:248–54.PubMedCrossRef

30.

Degnim AC, Kriffith KA, Newman L. Clinicopathologic features of metastasis in non sentinel lymph nodes of breast carcinoma patients: a metaanalysis. Cancer. 2003;98:2307–15.PubMedCrossRef

31.

Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.PubMedCrossRef

32.

Coutant C, Olivier C, Lambaudie E, Fondrinier E, Marchal F, Guillemin F, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–8.PubMedCrossRef

33.

Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462–8.PubMedCrossRef

34.

Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–8.PubMedCrossRef

35.

Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstan F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30.PubMedCrossRef

36.

Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2012;131:819–25.PubMedCrossRef

37.

Straver ME, Meijnen P, van Tienhoven G, van de Velde CJH, Mansel RE, Bogaerts J, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981–22023 AMAROS trial. Ann Surg Oncol. 2010;17:1854–61.PubMedCrossRef

38.

Cody HS III, Houssami N. Axillary management in breast cancer: what’s new for 2012? Breast. 2012;21:411–5.PubMedCrossRef

39.

Pazaiti A, Fentiman IS. Which patients need an axillary clearance after sentinel node biopsy? Int J Breast Cancer. 2011. doi:10.4061/2011/195892.PubMed

40.

McGhan LJ, Dueck AC, Gray RI, Wasif N, McCullough AE, Pockaj BA. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2011. doi:10.1002/jso.22131.PubMed

41.

Turner RR, Giuliano AE. Intraoperative pathologic examination of the sentinel lymph node. Ann Surg Oncol. 1999;5:670–2.CrossRef

42.

Chao C, Wong SL, Ackermann D, Simpson D, Carter MB, Brown CM, et al. Utility of intraoperative frozen section analysis of sentinel lymph nodes in breast cancer. Am J Surg. 2001;182:609–15.PubMedCrossRef

43.

Noguchi M. Is axillary dissection unnecessary in patients with a positive sentinel lymph node? Breast Cancer. 2012. doi:10.1007/s12282-012-0351-4.

Title: The changing role of axillary lymph node dissection for breast cancer
Authors: Masakuni Noguchi
Emi Morioka
Yukako Ohno
Miki Noguchi
Yasuharu Nakano
Takeo Kosaka
Publication date: 01-01-2013
Publisher: Springer Japan
Published in: Breast Cancer / Issue 1/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-012-0416-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

An uncommon case of T1b breast cancer with diabetic mastopathy in type II diabetes mellitus

BI-RADS-MRI terminology and evaluation of intraductal carcinoma and ductal carcinoma in situ

Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria

Preoperative evaluation for intraductal spread of breast cancer through current imaging tests: their strengths and limitations

Self-efficacy mediates the relationship between behavioral processes of change and physical activity in older breast cancer survivors

Nipple- or skin-sparing mastectomy and immediate breast reconstruction by the “moving window” operation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer